Walpar Nutritions Limited (NSE:WALPAR)

Market Cap	325.38M -34.7%
Revenue (ttm)	757.46M +17.7%
Net Income	23.31M -5.7%
EPS	2.49 -6.5%
Shares Out	9.39M
PE Ratio	13.94
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Open	31.35
Previous Close	33.00
Day's Range	31.35 - 34.65
52-Week Range	31.35 - 53.30
Beta	-0.56
Analysts	n/a
Price Target	n/a
Earnings Date	May 28, 2026

About Walpar Nutritions

Walpar Nutritions Limited manufactures and trades pharmaceutical, nutraceutical, herbal, and ayurvedic commodities in India. The company offers G-Flora, a probiotic blend for gut health and immunity; Inosia-F, an inositol supplement; Inovam Plus, a multivitamin; Ironica-CR, controlled-release iron supplement; Myobest, muscle support formula; Ovality, ovarian health support; Ovanyx-F, a female reproductive health supplement; Ovacon-F, women's fertility support; PCOS Care Forte, a PCOS support; Procive-F, female fertility enhancement supplement; ...

• Industry: Pharmaceutical Preparations
• Founded: 2009
• Country: India
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WALPAR

Financial Performance

In fiscal year 2025, Walpar Nutritions's revenue was 719.60 million, an increase of 14.93% compared to the previous year's 626.13 million. Earnings were 23.24 million, an increase of 46.92%.